Mallinckrodt plc / Ikaria, Inc.

Hypoxic Respiratory Failure with Pulmonary Hypertension in Term/Near-Term Neonates

Disease Overview

Persistent pulmonary hypertension of the newborn (PPHN) is a failure of normal post-birth circulatory transition where elevated pulmonary vascular resistance causes right-to-left shunting and severe hypoxemia in term and near-term neonates. It remains a major cause of neonatal morbidity and mortality with reported death rates of 4-33%, and inhaled nitric oxide is the standard pharmacologic vasodilator alongside ECMO rescue.

Competitive Landscape

INOMAX held a near-monopoly position in US neonatal inhaled nitric oxide (iNO) therapy at deal close in 2015, marketed as an integrated drug-device-service offering bundling cylinder gas, the INOmax DSIR delivery system, technical support, and 24/7 service. Competing modalities included extracorporeal membrane oxygenation (ECMO) as rescue therapy and high-frequency oscillatory ventilation (HFOV), but no approved pharmacologic substitute existed for FDA-labeled neonatal hypoxic respiratory failure with pulmonary hypertension. The competitive threat was patent and entrant risk: Praxair (later acquired by Linde) was developing a competing iNO product, and Bellerophon Therapeutics targeted PAH adult populations with INOpulse. Beyond Air's LungFit PH (FDA-cleared 2022) eventually broke the cylinder paradigm using ambient-air plasma ionization, and INOMAX patents were ultimately invalidated in court. At deal time, however, FierceBiotech and FiercePharma framed the $2.3B price as steep but defensible given INOMAX's $150M+ accretive sales contribution and the drug-device moat. The acquisition complemented Mallinckrodt's existing Acthar Gel hospital franchise and extended into neonatal critical care.